The clinical trials research area with FNI undertakes more than thirty trials at any one time. These consist of investigator initiated studies as well as those initiated by commercial interests. Investigator driven trials such as ARCH in which patients in whom the mechanism of ischaemic TIA or stroke is most likely due to the presence of aortic arch atheroma are randomised to receive either combination antiplatelet therapy or the more traditional anticoagulant, warfarin continue.
The team's main interest is in acute stroke therapy (neuroprotection and thrombolysis) as well as secondary prevention. As part of our approach to the former, neuroimaging modalities are being used (particularly MRI) to provide important “proof of concept” information before embarking upon larger clinical trials.
A major focus of the group is A Very Early Rehabilitation Trial (AVERT) which is now in Phase III. In this innovative study, the hypothesis that earlier and more intensive mobilisation of stroke patients will improve outcomes, and be cost effective, is being tested (n=2104).
In the secondary prevention field, a large number of studies are conducted using antiplatelet agents and anticoagulants as well as agents designed to reduce the risk of surgical procedures such as carotid endarterectomy.
Any clinical trial is highly dependent upon collaborative links with a large number of centres both within Australia and internationally. In this regard, we are particularly fortunate in having the Australian Stroke Trials Network (ASTN) and well established international linkages.
“The great men of science are supreme artists.”
